12-Week Study of Omega-3 Fatty Acid EPA Treatment for Depression in Obese Adults with Low Omega-3 Levels

What this Trial Is About

Researchers are evaluating the effect of a 12-week treatment with n-3 polyunsaturated fatty acids specifically eicosapentaenoic acid, EPA on depressive symptoms in overweight or obese adults who have major depressive disorder and low omega-3 fatty acid status. This randomized, placebo-controlled trial also aims to explore how genetics, lifestyle, nutrition, and gut microbiota influence these effects in a Taiwanese cohort. Participants are randomly assigned to one of two groups one receiving 2 grams per day of EPA through four capsules, and the other receiving a placebo at the same dosage and schedule. The treatment period lasts for 12 weeks, during which participants take their assigned capsules daily. During the study, depression severity is assessed at baseline and at weeks 2, 4, 8, and 12. Blood samples are collected at the start and end of the study to measure omega-3 levels. Additional assessments include stress, food intake, pleasure, and fatigue measurements at the same intervals. The trial monitors participants closely to evaluate changes in depressive symptoms and related factors over the treatment period.

NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status